SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that data from clinical trials of the company's investigational compounds XL184, XL147, XL765, XL228 and XL139 will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8 in Chicago, Illinois. Lead compound XL184 will be the subject of four separate presentations, including an oral presentation of clinical data from the ongoing phase 2 trial in patients with progressive glioblastoma. PI3K pathway inhibitors XL147 and XL765 will be the subject of six separate presentations. Exelixis is co-developing XL184 and XL139 with Bristol-Myers Squibb Company. Sanofi-aventis has a worldwide, exclusive license to XL147 and XL765.
